Inotiv Cleared by SEC in Importation Probe

Inotiv ( (NOTV) ) just unveiled an update.

Inotiv, Inc. was investigated by the SEC regarding its importation practices of non-human primates from Asia, specifically concerning compliance with the U.S. Foreign Corrupt Practices Act. The investigation, which began with a voluntary request in May 2023, concluded on June 2, 2025, with the SEC’s Division of Enforcement deciding not to recommend any enforcement action against the company.

The most recent analyst rating on (NOTV) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Inotiv stock, see the NOTV Stock Forecast page.

Spark’s Take on NOTV Stock

According to Spark, TipRanks’ AI Analyst, NOTV is a Neutral.

Inotiv’s financial performance is the most significant factor, with persistent challenges in revenue, profitability, and cash flow. Technical analysis reflects some positive momentum, but valuation concerns due to ongoing losses and no dividend yield weigh heavily. The earnings call highlighted positive developments, but issues in certain segments persist.

To see Spark’s full report on NOTV stock, click here.

More about Inotiv

Inotiv, Inc. operates in the life sciences industry, focusing on providing contract research services and products to pharmaceutical, biotechnology, and medical device companies. The company is involved in the importation of non-human primates for research purposes.

Average Trading Volume: 743,721

Technical Sentiment Signal: Strong Sell

Current Market Cap: $93.1M

See more data about NOTV stock on TipRanks’ Stock Analysis page.